Catalyst overview
Research summary
This catalyst tracks a Phase 1/2 data readout for CAB-EpCAM x CAB-CD3 TCE (BA3182) in Carcinoma . The expected timing is based on the latest available company guidance and may change.
Q2'25- Dose escalation continues at 1.2mg flat dosing. 10/20/25- Interim Ph1 results presented at ESMO'25. Dose escalation continues. 11/13/25:- BA3182 Phase 1 adenocarcinoma trial (NCT05808634); dose-escalation readout expected H1 2026, expansion readouts later 2026. 03/31/26:- Continuing Phase 1 BA3182 adenocarcinoma trial; enrollment timing under review amid strategic process.
Verification
Confirm timing and program details against the company announcement or filing.